Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 54.58

-1.0%

Nov 10 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (12148)	6/23/2004 8:43:27 PM
From: hmpa	Read Replies (1) of 52153

Actually the whole KOSN before-the-fact drop and today's rise might have been the result not of some actual news leak but rather of nebulous (and maybe innocuous) comments from someone at a bar or wherever (maybe at ASCO since the slide began at ASCO time) which led to a snowball. Yesterdays' Reuters release on the issue had this comment: <snip> Needham & Co. analyst Mark Monane said the Roche statement should allay Wall Street fears that the setback might spell the end of Kosan's crucial relationship with the Swiss drug company. "Overall, it's not good news, but not as bad as the Street had anticipated, which was that the relationship was in question, " Monane said.<snip>

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next